Q-omics provides the consensus-scored SUGT1P4-STRA6LP profile across patient tissues and cancer cell-line models. SUGT1P4-STRA6LP expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SUGT1P4-STRA6LP is differentially expressed in 10, with the highest sampling consensus in THCA. Additionally, SUGT1P4-STRA6LP RNA expression shows 20,417 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, THCA, and UVM as cancer lineages where SUGT1P4-STRA6LP shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SUGT1P4-STRA6LP — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SUGT1P4-STRA6LP survival associations across molecular data types. SUGT1P4-STRA6LP RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SUGT1P4-STRA6LP RNA expression–survival associations across cancer types. High SUGT1P4-STRA6LP expression shows unfavorable associations in UCEC, LGG, HNSC, KIRC and KICH, but favorable associations in PAAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for SUGT1P4-STRA6LP RNA expression.
This table summarizes SUGT1P4-STRA6LP tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SUGT1P4-STRA6LP. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SUGT1P4-STRA6LP shows lower tumor expression in THCA, BRCA, KIRP, KIRC, LUAD and LUSC. The THCA box plot shows higher SUGT1P4-STRA6LP RNA expression in normal versus tumor tissue (log2 FC = −0.765, t-test p < 0.001).
This table shows molecular features associated with SUGT1P4-STRA6LP in patient tissues and cancer cell lines. In patient samples, SUGT1P4-STRA6LP shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
